Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Grows By 86.8%

The Oncology Institute, Inc. (NASDAQ:TOIGet Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 324,100 shares, an increase of 86.8% from the December 15th total of 173,500 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.2 days.

Insider Activity

In related news, Director Brad Hively acquired 250,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the transaction, the director now owns 616,753 shares of the company’s stock, valued at approximately $104,848.01. The trade was a 68.17 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.50% of the company’s stock.

Institutional Trading of Oncology Institute

A hedge fund recently raised its stake in Oncology Institute stock. HighTower Advisors LLC lifted its position in The Oncology Institute, Inc. (NASDAQ:TOIFree Report) by 190.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 81,362 shares of the company’s stock after acquiring an additional 53,382 shares during the period. HighTower Advisors LLC owned about 0.11% of Oncology Institute worth $27,000 as of its most recent SEC filing. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Trading Up 8.1 %

Shares of Oncology Institute stock traded up $0.03 on Wednesday, reaching $0.40. 2,596,948 shares of the company were exchanged, compared to its average volume of 711,372. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $2.45. The firm has a market capitalization of $30.22 million, a price-to-earnings ratio of -0.51 and a beta of 0.13. The stock has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.33.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

Featured Articles

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.